Dermatitis

Related records

Broader conditions (7)

• Disease
• Disease by body system or component
• Disease by developmental or physiological process
• Human disease
• Inflammatory disease
• Integumentary system disorder
• Skin disorder

Narrower conditions (212)

• 2-hydroxyethyl methacrylate sensitization
• Acanthosis nigricans
• Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome
• Acne
• Acne keloid
• Acneiform dermatitis
• Acquired angioedema
• Acquired angioedema type 1
• Acquired angioedema type 2
• Acquired angioedema with C1Inh deficiency
• Acquired epidermolysis bullosa
• Acrodermatitis
• Acrodermatitis chronica atrophicans
• Actinic lichen planus
• Acute generalized exanthematous pustulosis
• Acute idiopathic urticaria
• Acute lichenoid pityriasis
• Adermatopathic dermatomyositis
• Adult acne
• Adult dermatomyositis

Trials (243)

• 35 kDa Hyaluronan Fragment (HA35) Reduces Chronic Inflammation of Skin
• 4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
• A Basket Trial of Vunakizumab in Inflammatory Skin Diseases
• A Clinical Evaluation of 3M Cavilon Advanced Barrier Film for the Treatment of Incontinence Associated Dermatitis (IAD)
• A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis
• A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis
• A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis
• A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis
• A Phase 1/2 Study of E6005 in Pediatric Subjects With Atopic Dermatitis
• A Phase 2 Study of E6005 in Patients With Atopic Dermatitis
• A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
• A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
• A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
• A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
• A Phase I Study of Single Subcutaneous Dose of SHR-1894 in Healthy Subjects
• A Phase I Study to Assess the Safety and Tolerability of Topical CRx-197 Formulations in Healthy Volunteers
• A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM)
• A Randomised Clinical Trial in a Population of Health Care Workers With Hand Eczema
• A Randomized Controlled Trial Comparing the Effectiveness and Safety of Topical Tacrolimus 0.03% Versus Crisaborole 2% in Patients With Mild to Moderate Atopic Dermatitis Over 8 Weeks
• A Single-Center, Exploratory Study to Analyze the Dynamics of Skin Microflora Following Exposure to Surfactants

Approved drugs (11)

• Betamethasone acetate
• Dexamethasone
• Dimethicone
• Gentamicin sulfate
• Hydrocortisone
• Methylprednisolone acetate
• Methylprednisolone sodium succinate
• Salicylic acid
• Selenium sulfide
• Triamcinolone acetonide
• Zinc oxide

Drugs in development (34)

• Acitretin Phase 2
• Adriforant Phase 1
• Apremilast Phase 2
• Azathioprine Early phase 1
• Bepotastine Phase 3
• Butenafine hydrochloride Phase 3
• Cephalexin Phase 2
• Cetirizine Phase 3
• Clemastine Phase 3
• Crisaborole Phase 2
• Desloratadine Phase 3
• Doxycycline Phase 2
• Dupilumab Phase 3
• Etokimab Phase 1
• Gusacitinib Phase 2
• Idrebormilast Phase 1
• Ketoconazole Phase 3
• Ketotifen fumarate Phase 3
• Levocetirizine Phase 3
• Methotrexate Early phase 1

Other linked drugs (7)

• Bilastine
• Bufexamac
• Delgocitinib
• Epinastine hydrochloride
• Fexofenadine hydrochloride
• Levocetirizine dihydrochloride
• Olopatadine hydrochloride